#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Prodromal Alzheimer's disease Microscopic polyangiitis Deafness B-cell type acute leukaemia Colon cancer Peritoneal neoplasm Cognitive disorder Paroxysmal nocturnal haemoglobinuria Tourette's disorder Immune-mediated renal disorder Ischaemic stroke Antithrombin III deficiency Adenocarcinoma pancreas Central nervous system lymphoma Hypoparathyroidism More trials…

    Learn about Rare Diseases

    Bronchopulmonary dysplasia – Basic Information Fabry’s disease – Trials in Disease Rhabdoid tumour – Trials in Disease Adrenogenital syndrome – Life with Disease Hereditary neuropathic amyloidosis – Life with Disease Mucous membrane pemphigoid – Diagnostics Systemic sclerosis pulmonary – Basic Information Toxic epidermal necrolysis – Life with Disease Biotinidase deficiency – Treatment Medulloblastoma recurrent – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    IHMA-2121771-1 Nms-03305293 Idarubicin Hydrochloride Acenocoumarol SONLICROMANOL HYDROCHLORIDE Cls12311 Bifikafusp Alfa Posaconazole Ribonucleic Acid K10 Amisulpride Chlorhexidine Dihydrochloride VRDN-003 Olopatadine MB-CART2219.1 Netupitant Chloroprocaine Hydrochloride Sodium Butyrate Grwd5769 CIRTUVIVINT VERT-002 More therapies…

    Learn about Your Condition

    Skin neoplasm excision Tendon injury Sjogren's syndrome Leiomyosarcoma recurrent Osteosarcoma recurrent Cervical dysplasia Portal hypertension Tinnitus Biliary tract disorder Hypertriglyceridaemia Large cell lung cancer stage 0 Suicidal ideation Dystonic tremor Angina pectoris VEXAS syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Fakultni Nemocnice Plzen

Fakultni Nemocnice Plzen

Edvarda Benese 1128/13, Jizni Predmesti, Plzen, 301 00, Czechia

Want to learn more about this study or check if you can participate? Contact us.

  • Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

    Recruiting

    3 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    • Teclistamab
    Czechia France Germany Greece Italy Poland +1

  • Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

    Recruiting

    3 1 1
    Investigated Diseases:
    • Neovascular age-related macular degeneration
    Investigated Drugs:
    • Aflibercept
    Czechia Hungary Latvia Lithuania Poland Slovakia +1

  • Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

    Recruiting

    4 1
    Investigated Drugs:
    • LUNSEKIMIG
    Czechia Germany Greece Lithuania The Netherlands Norway +4

  • Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Nilotinib
    • Asciminib Hydrochloride
    • Imatinib
    Austria Bulgaria Czechia Denmark France Germany +8

  • Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Bulgaria Czechia Finland France +10

  • A study comparing BGB-11417 and zanubrutinib with venetoclax and acalabrutinib for patients with previously untreated chronic lymphocytic leukemia

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • Acalabrutinib
    • Venetoclax
    Czechia France Germany Italy The Netherlands Poland +3

  • A Study Testing How Well Bimekizumab Works and How Safe It Is for Adults with Palmoplantar Pustulosis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Bimekizumab
    Czechia Denmark France Germany Hungary Italy +2

  • Long-term safety and effectiveness study of ritlecitinib in children with severe alopecia areata who completed previous trials B7981027 or B7981031

    Recruiting

    3 1
    Czechia France Italy Poland Spain

  • Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Linvoseltamab
    • Daratumumab
    • Dexamethasone
    Austria Belgium Croatia Czechia Denmark Estonia +10

  • Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Azacitidine
    • BLEXIMENIB
    • Venetoclax
    Austria Belgium Czechia Denmark France Germany +6
1 2 3 … 10
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!